Levosimendan is an inodilator medication primarily used in Europe and other international markets for the short-term treatment of acutely decompensated severe chronic heart failure. It increases the heart’s pumping strength without significantly increasing myocardial oxygen demand, while also relaxing blood vessels to reduce workload on the heart
Product Name:Levosimendan
Other Name:(-)-OR-1259, (R)-Simendan, 2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile, OR 1259, R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile
Assay: ≥98% (HPLC)
Molecular Formula:C14H12N6O
Molecular Weight:280.28
Packing:1mg;5mg;10mg;50mg;100mg,1g or according to customer’s detail requirement.